ddI didanosine DHHS Department of Health and Human Services DNA deoxyribonucleic acid dNTP 2' deoxynucleoside triphosphate DRV, D darunavir DTG dolutegravir DXA dual-energy x-ray absorptiometry EASC European AIDS Clinical Society EC50 concentration of a compound inhibiting virus replication by 50% EOP2 End of Phase 2 EVG, E elvitegravir (Vitekta) E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated) EFV efavirenz eGFR estimated glomerular filtration rate eGFRCG estimated glomerular filtration rate calculated using the equation ESRD end-stage renal disease EU European Union EVG, E elvitegravir (Vitekta) FAS Full Analysis Set FDA Food and Drug Administration FDC combination FTC, F emtricitabine (Emtriva) FTC-DP emtricitabine diphosphate GCP Good Clinical Practice
ddI didanosine DHHS Department of Health and Human Services DNA deoxyribonucleic acid dNTP 2' deoxynucleoside triphosphate DRV, D darunavir DTG dolutegravir DXA dual-energy x-ray absorptiometry EASC European AIDS Clinical Society EC50 concentration of a compound inhibiting virus replication by 50% EOP2 End of Phase 2 EVG, E elvitegravir (Vitekta) E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated) EFV efavirenz eGFR estimated glomerular filtration rate eGFRCG estimated glomerular filtration rate calculated using the equation ESRD end-stage renal disease EU European Union EVG, E elvitegravir (Vitekta) FAS Full Analysis Set FDA Food and Drug Administration FDC combination FTC, F emtricitabine (Emtriva) FTC-DP emtricitabine diphosphate GCP Good Clinical Practice
auspar-elvitegravir-160628-cer.docx